Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0HZMTS
ADC Name
IC1-MMAE
Synonyms
IC1 MMAE; IC1MMAE
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Triple negative breast cancer [ICD11:2C60-2C65]
Investigative
Drug-to-Antibody Ratio
3.92
Antibody Name
Chimeric ICAM1 Anti-ody (clone #R6.5)
  Antibody Info 
Antigen Name
Intercellular adhesion molecule 1 (ICAM1)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Vedotin
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 62.76
%
MDA-MB-436 cells
Metastasis of ductal carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 96.7
%
MDA-MB-231 cells
Breast adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 99.5
%
MDA-MB-436 cells
Metastasis of ductal carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 99.5
%
MDA-MB-436 cells
Metastasis of ductal carcinoma
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
13.1
pM
MDA-MB-436 cells
Metastasis of ductal carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.22
nM
MDA-MB-157 cells
Breast carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.25
nM
MDA-MB-468 cells
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 62.76% (Day 25) Positive ICAM1 expression (ICAM1 +++/++)
Method Description
IC1-MMAE (1 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of MDA-MB-436 or MDA-MB-231 cells with ICAM1 expression with high expression.
In Vivo Model MDA-MB-436 CDX model
In Vitro Model Metastasis of ductal carcinoma MDA-MB-436 cells CVCL_0623
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 96.70% (Day 25) Positive ICAM1 expression (ICAM1 +++/++)
Method Description
IC1-MMAE (5 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of MDA-MB-436 or MDA-MB-231 cells with ICAM1 expression with high expression.
In Vivo Model MDA-MB-231 CDX model
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.50% (Day 25) Positive ICAM1 expression (ICAM1 +++/++)
Method Description
IC1-MMAE (10 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of MDA-MB-436 or MDA-MB-231 cells with ICAM1 expression with high expression.
In Vivo Model MDA-MB-436 CDX model
In Vitro Model Metastasis of ductal carcinoma MDA-MB-436 cells CVCL_0623
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.50% (Day 25) Positive ICAM1 expression (ICAM1 +++/++)
Method Description
IC1-MMAE (5 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of MDA-MB-436 or MDA-MB-231 cells with ICAM1 expression with high expression.
In Vivo Model MDA-MB-436 CDX model
In Vitro Model Metastasis of ductal carcinoma MDA-MB-436 cells CVCL_0623
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 13.10 pM Positive ICAM1 expression (ICAM1 +++/++)
Method Description
In vitro cytotoxicity of four ICAM1 ADCs against a panel of four human TNBC cell lines.
In Vitro Model Metastasis of ductal carcinoma MDA-MB-436 cells CVCL_0623
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.22 nM Positive ICAM1 expression (ICAM1 +++/++)
Method Description
In vitro cytotoxicity of four ICAM1 ADCs against a panel of four human TNBC cell lines.
In Vitro Model Breast carcinoma MDA-MB-157 cells CVCL_0618
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.25 nM Positive ICAM1 expression (ICAM1 +++/++)
Method Description
In vitro cytotoxicity of four ICAM1 ADCs against a panel of four human TNBC cell lines.
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
References
Ref 1 A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo. Sci Adv. 2023 May 5;9(18):eabq7866. doi: 10.1126/sciadv.abq7866. Epub 2023 May 5.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.